

Helle D Zacho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1959218/publications.pdf>

Version: 2024-02-01

63
papers

1,727
citations

394421

19
h-index

289244

40
g-index

65
all docs

65
docs citations

65
times ranked

2052
citing authors

#	ARTICLE	IF	CITATIONS
1	Observer experience and accuracy of ¹⁸ F-sodium-fluoride PET/CT for the diagnosis of bone metastases in prostate cancer. <i>Nuclear Medicine Communications</i> , 2022, 43, 680-686.	1.1	1
2	¹⁸ F-FDG PET/CT in a Case of Urothelial Carcinoma in the Urachus Presenting as Colon Cancer. <i>Diagnostics</i> , 2022, 12, 31.	2.6	0
3	Use of ¹⁸ F-NaF PET in the staging of skeletal metastases of newly diagnosed, high-risk prostate cancer patients: a nationwide cohort study. <i>BMJ Open</i> , 2022, 12, e058898.	1.9	3
4	Influence of Prior Imaging Information on Diagnostic Accuracy for Focal Skeletal Processes—A Retrospective Analysis of the Consistency between Biopsy-Verified Imaging Diagnoses. <i>Diagnostics</i> , 2022, 12, 1735.	2.6	0
5	Combination of Forced Diuresis with Additional Late Imaging in ⁶⁸ Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1252-1257.	5.0	26
6	Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2978-2989.	6.4	58
7	Authors' reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2307-2308.	6.4	0
8	Validity of negative bone biopsy in suspicious bone lesions. <i>Acta Radiologica Open</i> , 2021, 10, 205846012110306.	0.6	5
9	Lesion detection in ¹⁸ F-sodium fluoride bone imaging. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 78-85.	1.1	1
10	Diagnostic Accuracy of ⁶⁸ Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	7.1	138
11	The frequency and malignancy rate of incidental focal breast lesions identified by ¹⁸ F-fluorodeoxyglucose positron emission tomography. <i>Nuclear Medicine Communications</i> , 2021, 42, 93-100.	1.1	1
12	⁶⁸ Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. <i>World Journal of Urology</i> , 2020, 38, 939-948.	2.2	23
13	⁶⁸ Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer—a modified protocol compared with the common protocol. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 624-631.	6.4	26
14	The Ability of the Toe-Brachial Index to Predict the Outcome of Treadmill Exercise Testing in Patients with a Normal Resting Ankle-Brachial Index. <i>Annals of Vascular Surgery</i> , 2020, 64, 263-269.	0.9	1
15	Observer Agreement and Accuracy of ¹⁸ F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 344-349.	5.0	16
16	⁶⁸ Ga-PSMA PET/CT Uptake in the Ureter Caused by Ligand Expression in Urothelial Cancer. <i>Clinical Nuclear Medicine</i> , 2020, 45, e43-e45.	1.3	7
17	Reporting and handling of equivocal imaging findings in diagnostic studies of bone metastasis in prostate cancer. <i>Acta Radiologica</i> , 2020, 61, 1096-1104.	1.1	5
18	Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastases. <i>Nuclear Medicine Communications</i> , 2020, 41, 1005-1009.	1.1	5

#	ARTICLE	IF	CITATIONS
19	PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. <i>Cancer Imaging</i> , 2020, 20, 10.	2.8	59
20	Added value of ⁶⁸ Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous ^{99m} Tc bone scintigraphy. <i>EJNMMI Research</i> , 2020, 10, 31.	2.5	31
21	Risk factors and haemodynamic variables in patients with low toe-brachial index but normal ankle-brachial index. <i>Atherosclerosis</i> , 2019, 289, 21-26.	0.8	8
22	No Added Value of ¹⁸ F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1713-1716.	5.0	14
23	Giant Hepatic Artery Aneurysm. <i>Diagnostics</i> , 2019, 9, 53.	2.6	3
24	Assessment of ⁶⁸ Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	7.1	493
25	Reply: Off-Target Report on ¹⁸ F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1836-1836.	5.0	0
26	Prospective comparative study of ¹⁸ F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. <i>Acta Oncologica</i> , 2018, 57, 1063-1069.	1.8	9
27	⁶⁸ Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 911-922.	1.2	56
28	Bone Flare to Androgen Deprivation Therapy in Metastatic, Hormone-Sensitive Prostate Cancer on ⁶⁸ Ga-Prostate-Specific Membrane Antigen PET/CT. <i>Clinical Nuclear Medicine</i> , 2018, 43, e404-e406.	1.3	22
29	⁶⁸ Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 579-585.	1.3	24
30	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , The, 2018, 19, e534-e545.	10.7	98
31	Reporting and Handling of Indeterminate Bone Scan Results in the Staging of Prostate Cancer: A Systematic Review. <i>Diagnostics</i> , 2018, 8, 9.	2.6	5
32	Prospective comparison of ⁶⁸ Ga-PSMA PET/CT, ¹⁸ F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1884-1897.	6.4	76
33	Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review. <i>BMJ Supportive and Palliative Care</i> , 2017, 7, bmjspcare-2015-000957.	1.6	6
34	Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT. <i>EJNMMI Research</i> , 2017, 7, 1.	2.5	64
35	⁶⁸ Ga-PSMA PET/CT Uptake in Intramuscular Myxoma Imitates Prostate Cancer Metastasis. <i>Clinical Nuclear Medicine</i> , 2017, 42, 487-488.	1.3	19
36	⁶⁸ Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111

#	ARTICLE	IF	CITATIONS
37	A Comprehensive Safety Evaluation of 68Ga-Labeled Ligand Prostate-Specific Membrane Antigen 11 PET/CT in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, 520-524.	1.3	14
38	Observer agreement of treatment responses on planar bone scintigraphy in prostate cancer patients. <i>Nuclear Medicine Communications</i> , 2017, 38, 215-221.	1.1	5
39	68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review. <i>Molecular and Clinical Oncology</i> , 2017, 7, 67-72.	1.0	2
40	Reply by the Authors. <i>Urology</i> , 2017, 104, 243-244.	1.0	0
41	Comparison of two methods based on photoplethysmography for the diagnosis of peripheral arterial disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 622-627.	1.2	4
42	Author Reply. <i>Urology</i> , 2017, 108, 141.	1.0	0
43	Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography for staging of high-risk prostate cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 498-501.	1.0	2
44	Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence. <i>Clinical Nuclear Medicine</i> , 2017, 42, 221-222.	1.3	31
45	Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study. <i>Urology</i> , 2017, 108, 135-141.	1.0	10
46	Unexplained Bone Pain Is an Independent Risk Factor for Bone Metastases in Newly Diagnosed Prostate Cancer: A Prospective Study. <i>Urology</i> , 2017, 99, 148-154.	1.0	6
47	Avid 18F-FDG Uptake in Idiopathic Tumoral Calcinosis Mimicking Lymph Node Metastasis. <i>Diagnostics</i> , 2017, 7, 60.	2.6	2
48	Prospective evaluation of computer-assisted analysis of skeletal lesions for the staging of prostate cancer. <i>BMC Medical Imaging</i> , 2017, 17, 40.	2.7	6
49	Diagnostic test accuracy study of F-sodium fluoride PET/CT, Tc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 218-227.	1.0	31
50	18F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study. <i>BMC Cancer</i> , 2016, 16, 10.	2.6	8
51	Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: A prospective study in patients undergoing radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 29-32.	1.0	5
52	Safety and tolerability of regadenoson for myocardial perfusion imaging – first Danish experience. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 180-186.	1.2	7
53	Computer-assisted interpretation of planar whole-body bone scintigraphy in patients with newly diagnosed prostate cancer. <i>Nuclear Medicine Communications</i> , 2015, 36, 679-685.	1.1	8
54	Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI. <i>Nuclear Medicine Communications</i> , 2015, 36, 1084-1090.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer. <i>Nuclear Medicine Communications</i> , 2015, 36, 445-451.	1.1	13
56	Prospective Multicenter Study of Bone Scintigraphy in Consecutive Patients With Newly Diagnosed Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, 26-31.	1.3	37
57	Large pore dermal microdialysis and liquid chromatography-tandem mass spectroscopy shotgun proteomic analysis: a feasibility study. <i>Skin Research and Technology</i> , 2013, 19, 424-431.	1.6	7
58	Chronic intestinal ischemia and splanchnic blood-flow: Reference values and correlation with body-composition. <i>World Journal of Gastroenterology</i> , 2013, 19, 882.	3.3	10
59	Validation of ^{99m} Technetium-labeled mebrofenin hepatic extraction method to quantify meal-induced splanchnic blood flow responses using a porcine model. <i>Journal of Applied Physiology</i> , 2012, 112, 877-882.	2.5	3
60	Functional versus radiological assessment of chronic intestinal ischaemia. <i>Clinical Physiology and Functional Imaging</i> , 2010, 30, 116-121.	1.2	10
61	Tissue viability imaging for assessment of pharmacologically induced vasodilation and vasoconstriction in human skin. <i>Microvascular Research</i> , 2010, 80, 499-504.	2.5	13
62	Absorption and metabolism of benzoic acid in growing pigs ¹ . <i>Journal of Animal Science</i> , 2009, 87, 2815-2822.	0.5	46
63	Chronic intestinal ischaemia: diagnosis. <i>Clinical Physiology and Functional Imaging</i> , 2008, 28, 71-75.	1.2	15